Johnson & Johnson has received FDA (food and drug administration federal agency) approval for a new treatment option for adults newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant in the United State.

The treatment, Darzalex Faspro, used in combination with other therapies has shown in a Phase 3 study to improve the depth and durability of patient responses and reduce the risk of disease progression or death.

Multiple myeloma remains incurable and is the second most common blood cancer worldwide. This year alone, over 188,000 people globally are expected to be diagnosed, with more than 121,000 lives lost.

While there is still work to do, advances like this represent real progress, offering more time, better quality of life, and renewed hope for patients and families affected by blood cancer.

At Kevin Kararwa Leukaemia Trust, we believe that every step forward in research matters and we stand with everyone affected by blood cancer, advocating for better outcomes, supporting patients and families, and working to ensure no one is left behind.

🧡 Hope is built through research.
🧡 Lives are saved through action.